Technology
Health
Pharmaceutical

Ovid Therapeutics

$1.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (2.63%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell OVID and other stocks, options, ETFs, and crypto commission-free!

About

Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Employees
55
Headquarters
New York, New York
Founded
2014
Market Cap
46.84M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
104.72K
High Today
$1.98
Low Today
$1.89
Open Price
$1.90
Volume
65.08K
52 Week High
$11.45
52 Week Low
$1.72

Collections

Technology
Health
Pharmaceutical
Therapy
Biopharmaceutical
2017 IPO
US
North America

News

Seeking AlphaMar 7

Ovid Therapeutics reports Q4 results

Ovid Therapeutics (NASDAQ:OVID): Q4 GAAP EPS of -$0.52. Cash, cash equivalents, and short-term investments of $72.5M including net proceeds from public offering Feb 2019 Press Release...

187
Simply Wall StFeb 27

Introducing Ovid Therapeutics, The Stock That Tanked 72%

Even the best investor on earth makes unsuccessful investments. But it would be foolish to simply accept every extremely large loss as an inevitable part of the game. We wouldn’t blame Ovid Therapeutics Inc. (NASDAQ:OVID) shareholders if they were still in shock after the stock dropped like a lead balloon, down 72% in just one year. While some investors are willing to stomach this sort of loss, they are usually professionals who spread their bets thinly. Because Ovid Therapeutics hasn’t been listed for many...

107
Associated PressFeb 20

Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock

NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the pricing of underwritten public offerings of (i) 12,500,000 shares of its common stock and (ii) 2,500 shares of its non-voting Series A Convertible Preferred Stock (“Series A stock”) (together, the “Offerings”). The public offering price of each share of common stock is $2.00 and...

361

Earnings

-$0.59
-$0.52
-$0.45
-$0.38
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.52 per share
Actual
-$0.52 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.